George Bakris on Muck Rack

George Bakris

Illinois
As seen in: Color Research & Application, Wiley Online Library, BMJ Open, MDPI, JAMA (The Journal of the American Medical Association), JAMA: Journal of the American Medical Association, Medscape, The New England Journal of Medicine, The European Heart Journal, The Lancet and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with George

Contact George, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Kidney and Survival Benefits of Semaglutide in Diabetes With Chronic Kidney Disease: FLOW Trial Cardiovascular Subgroup Analyses

|
By Katherine R. Tuttle, George Bakris, Florian M.M. Baeres
| JACC (Journal of the American College of Cardiology)
JACC Journals › JACC › Archives › Vol. 87 No. 21 Original Research Share on : JACC Volume 87, Number 21 Summary Box What has been established by the original and subsequent analyses from the FLOW trial? • The FLOW (Evaluate Renal Function with Semaglutide Once Weekly) trial was the first dedicated kidney outcomes trial with a glucagon-like peptide-1 (GLP-1) receptor agonist in a population with type 2 diabetes and CKD.
Open in Who Shared Issue with article?

The urinary albumin‐to‐creatinine ratio can direct personalized prevention and treatment for cardiovascular and chronic kidney disease

|
By Holly Kramer, George Bakris
| Wiley Online Library
Introduction Cardiovascular disease (CVD) affects almost 30 million United States (US) adults and accounted for over 900,000 deaths in 2020 [1]. Interventions, such as blood pressure control, reductions in smoking prevalence, and use of cholesterol-lowering medications, have successfully lowered CVD mortality rates over the past 60 years [2]. However, CVD burden is trending upward [3].
Open in Who Shared Issue with article?

THT 2025: SUMMIT: Impact of Obesity Severity on Tirzepatide in HFpEF

|
By Barry A. Borlaug, Mohammed El-Sheikh, George Bakris, John GF Cleland
| radcliffecvrm.com
Video Published: Views: 32 Likes: 0 Average (ratings) THT Conference 2025 - Outcomes assessing the effect of obesity severity on tirzepatide in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) show that patients on tirzepatide with a greater reduction in BMI and baseline waist-to-height ratio had greater improvements in exercise capacity and KCCQ quality of life scores.
Open in Who Shared Issue with article?
See all 99 licensed articles (107 Total)

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with George

Contact George, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified